Inquiry Focuses on Recently Closed Seven-Year Criminal Probe
WASHINGTON, DC – Energy and Commerce Committee Chairman Greg Walden (R-OR), Oversight and Investigations Subcommittee Chairman Tim Murphy (R-PA), Health Subcommittee Chairman Michael C. Burgess, M.D. (R-TX), and full committee Vice Chairman Joe Barton (R-TX), today sent a letter to Dr. Stephen Ostroff, Acting Commissioner at the Food and Drug Administration regarding the ongoing heparin contamination crisis.
“The Committee on Energy and Commerce continues to examine the heparin contamination crisis from 2007-2008 to help improve the Food and Drug Administration’s (FDA) strategy in combating economically-motivated adulteration of medical and food products imported to the U.S.,” write Walden, Murphy, Burgess, and Barton.
In March of 2016, the committee sent a letter to then FDA Commissioner Dr. Robert Califf raising questions about the then-ongoing criminal investigation. For years, the committee has tried to obtain documents from the FDA and has been consistently turned away because of an open Office of Criminal Investigations (OCI) investigation. In the letter, the committee leaders write requesting further information, including case files from the two recently closed FDA OCI matters involving heparin contamination.
To read a copy of the letter online, click here.